Abciximab: a reappraisal of its use in coronary care
Biologics: Targets & Therapy, 2008 Marco Valgimigli, Gianluca Campo, Matteo Tebaldi, Roberto Carletti, Chiara Arcozzi, Roberto Ferrari, Gianfranco PercocoCardiovascular Institute, Azienda Ospedaliera Universitaria S.
Marco Valgimigli +5 more
doaj +1 more source
Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention
Vascular Health and Risk Management, 2010 Jennifer Vergara-Jimenez, Pierluigi TricociDepartment of Medicine-Cardiology, Duke Clinical Research Institute, Durham, North Carolina, USAAbstract: Abciximab is a widely studied glycoprotein IIb/IIIa inhibitor, specifically in the setting of patients ...
Jennifer Vergara-Jimenez +1 more
doaj +1 more source
Comparative efficacy of eptifibatide and abciximab in primary angioplasty study
Research Reports in Clinical Cardiology, 2011 Rohan Jayasinghe1 Matias Yudi1 Sanjay Jayasinghe21Cardiology Department, Gold Coast Hospital, Griffith University, Queensland, Australia; 2Centre for Immunisation Research, Sydney, AustraliaBackground: Primary percutaneous intervention is the safest and ...
Rohan Jayasinghe +2 more
doaj +1 more source
Abciximab in the management of acute myocardial infarction with ST-segment elevation: evidence-based treatment, current clinical use, and future perspectives [PDF]
Therapeutics and Clinical Risk Management, 2014 Artur Dziewierz,1 Tomasz Rakowski,1 Dariusz Dudek2 12nd Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland; 2Department of Interventional Cardiology, Jagiellonian University Medical College, Krakow, Poland Abstract ...
Dziewierz A, Rakowski T, Dudek D
doaj +2 more sources
Incremental Propensity Score Interventions: A Primer for Pharmacoepidemiologists. [PDF]
Pharmacoepidemiol Drug SafABSTRACT Background In observational pharmacoepidemiology, estimating average treatment effects (ATEs) is often challenging due to a lack of practical positivity. In highly selective clinical settings, certain patients almost always or never receive treatment, causing ATE estimators to rely on unstable extrapolation.
Choi BY.
europepmc +2 more sources
Establishment of Haemonetics TEG 6s Reference Interval in Healthy Dogs. [PDF]
Vet Clin PatholABSTRACT Background A thromboelastogram viscoelastic monitor (the TEG 6s) has recently become available for use in veterinary patients. It is therefore necessary to establish reference intervals for the new device in each species where it is employed.
Whetstone K +6 more
europepmc +2 more sources
Retention of critical platelet hemostatic functions of amotosalen-UVA pathogen-reduced cryoprecipitated fibrinogen complex. [PDF]
TransfusionAbstract Background Cryoprecipitate Anti‐Haemophilic Factor (CRYO‐AHF) is enriched for fibrinogen, VWF, FVIII, FXIII and fibronectin, but has short post‐thaw expiration due to risk of transfusion‐transmitted infection (TTI) limiting availability for rapid treatment.
Tupin F +6 more
europepmc +2 more sources
Pathogen-reduced plasma, cryoprecipitate reduced for therapeutic plasma exchange. [PDF]
TransfusionAbstract Background Therapeutic plasma exchange (TPE) for thrombotic thrombocytopenic purpura (TTP) and auto‐immune disorders involves repeated patient exposure to allogenic plasma with the risk of transfusion‐transmitted infection (TTI).
Tupin F +6 more
europepmc +2 more sources
Abciximab induced severe thrombocytopenia in an elderly patient [PDF]
, 2022 Abciximab is a humanized monoclonal antibody which acts against αIIbβ3 receptor. The use of abciximab with percutaneous coronary interventions (PCI) has proven good results in patients.
Sen, Aastha +3 more
core +1 more source
Abciximab for thrombolysis during intracranial aneurysm coiling. [PDF]
, 2008 INTRODUCTION: Thrombotic events are a common and severe complication of endovascular aneurysm treatment with significant impact on patients' outcome.
Corkill, Rufus A +6 more
core +3 more sources